

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

## EQA round: BIL1/19 - Bilirubin Neonatal

Dead line: 22.02.2019

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Traceability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(215) Bilirubin total</b>					143									
Samples and groups	[µmol/L]													
<b>Sample A</b>		83,0	5,0	6,1	143									
(1) Abbott		84,4	2,5	2,9	13	0								
(58) Beckman Coulter (Olympus)		82,1	2,9	3,5	34	0								
(60) Roche		78,5	2,2	2,8	41	0								
(149) Siemens (Dade)		86,0	1,8	2,1	15	0								
(179) Siemens (Bayer)		89,6	3,0	3,3	19	0								
Other					21	0								
											3x 12, 1x 40, 4x 46, 3x 49, 1x 61, 1x 70, 1x 77, 1x 158, 1x 166, 2x 178, 3x 998			
<b>Sample B</b>		261	18	6,7	143									
(1) Abbott		262	9,1	3,5	13	0								
(58) Beckman Coulter (Olympus)		254	7,2	2,8	34	0								
(60) Roche		248	8,7	3,5	41	0								
(149) Siemens (Dade)		273	7,0	2,5	15	0								
(179) Siemens (Bayer)		291	11	3,7	19	0								
Other					21	0								
											3x 12, 1x 40, 4x 46, 3x 49, 1x 61, 1x 70, 1x 77, 1x 158, 1x 166, 2x 178, 3x 998			

st\_kn\_np

End of report

Printed: 02.03.2019